B. Riley FBR analyst David Buck downgraded Corcept Therapeutics to Neutral from Buy and cut his price target for the shares to $12 from $22. The analyst cites the company’s “disappointing” preliminary Q4 sales for the downgrade. The stock in midday trading is down 10%, or $1.16, to $10.02.
https://thefly.com/landingPageNews.php?id=2857897
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.